Breaking News Instant updates and real-time market news.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

, NVS

Novartis

$83.78

-0.29 (-0.34%)

08:33
08/29/18
08/29
08:33
08/29/18
08:33

Glaukos price target raised to $57 at Stephens after Novartis withdraws CyPass

Stephens analyst Chris Cooley raised his price target on Glaukos (GKOS) shares to $57 from $50 after Novartis' (NVS) Alcon unit withdrew the CyPass micro-stent from the market due to safety concerns. He estimates $40M-$50M in annual sales are now "in play" and see Glaukos as the most likely beneficiary, Cooley tells investors. He maintains an Overweight rating on Glaukos shares, which are up $17.35, or 39%, to $62.15 in pre-market trading.

GKOS

Glaukos

$44.79

-0.64 (-1.41%)

NVS

Novartis

$83.78

-0.29 (-0.34%)

  • 05

    Sep

  • 12

    Sep

GKOS Glaukos
$44.79

-0.64 (-1.41%)

08/13/18
PIPR
08/13/18
NO CHANGE
Target $46
PIPR
Overweight
Glaukos competitor received FDA approval on Friday, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien points out that privately-held Ivantis received FDA approval on Friday for its Hydrus stent to treat glaucoma. This should be a direct competitor to Glaukos' iStent, O'Brien tells investors in a research note. Though the timing of summer 2018 was expected, shares of Glaukos are likely to pull back today on the news, the analyst contends. O'Brien, however, does not expect too much of an impact on Glaukos sales from Ivantis given that the company still has to build out a commercial sales force and ensure proper training. In addition, the analyst believes "there is plenty of room for multiple players in this market." He remains constructive on Glaukos with an Overweight rating and $46 price target.
08/24/18
WELS
08/24/18
NO CHANGE
Target $50
WELS
Outperform
Ivantis counterclaim against Glaukos looks weak, says Wells Fargo
Following a review by his firm's patent consultant, Wells Fargo analyst Larry Biegelsen says Ivantis' counterclaim, alleging that Glaukos' new iStent inject product will infringe three Ivantis patents, appears weak. The Ivantis patents very specifically add a detail about the placement of the shunt, which reads as "too straightforward" or "obvious," the patent consultant told the analyst. As such, he believes the patents will ultimately be found invalid. Biegelsen keeps an Outperform rating on Glaukos with a $50 price target.
08/29/18
WBLR
08/29/18
NO CHANGE
WBLR
Outperform
CyPass market removal a 'clear positive' for Glaukos, says William Blair
William Blair analyst Brian Weinstein believes Alcon's voluntary global market withdrawal of its CyPass Micro-Stent for surgical glaucoma is a "clear positive for near-term numbers" at Glaukos (GKOS). If Glaukos' iStent takes all of the CyPass market share while it is off the market, the company could add as much as $50M in the U.S. alone to its 2019 total revenue of around $186M, Weinstein tells investors in a research note, while admitting this is a bullish stance. The analyst thinks the news this morning from Alcon should be viewed as a positive for Glaukos, as a major part of the short thesis was on competition in the core iStent market, mainly from Alcon. He keeps an Outperform rating on Glaukos shares.
08/29/18
PIPR
08/29/18
NO CHANGE
Target $55
PIPR
Overweight
Piper sees CyPass withdrawal as 'major boon' for Glaukos, ups target to $55
Piper Jaffray analyst Matt O'Brien views Alcon's immediate withdrawal of its CyPass stent for the treatment of glaucoma on safety concerns from a recently completed clinical study as a "major boon" for Glaukos (GKOS). The analyst suspects it will be several quarters before CyPass comes back to the market, with with a much narrower indication. This is a "major positive" for Glaukos as most of the clinicians using CyPass had been or are still using iStent from Glaukos, O'Brien tells investors in a research note. He anticipates many clinicians will quickly shift their volumes back to iSten, yielding "significant incremental revenues." Based on this morning's news, the analyst raised his price target for Glaukos shares to $55 from $46. He encourages investors to start or build positions in the name.
NVS Novartis
$83.78

-0.29 (-0.34%)

08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/23/18
MSCO
08/23/18
NO CHANGE
Target $45
MSCO
Overweight
Pfizer price target raised to $45 from $43 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Pfizer (PFE) and raised his price target to $45 based upon a 5-year CAGR for revenue growth of 3% and EPS growth of 7%. In a research note to investors, Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Additionally, he notes that political news has been "encouraging" as of late, with President Trump tweeting on July 19 "Thank you to Novartis (NVS) for not increasing your prices on prescription drugs. Likewise to Pfizer." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.

TODAY'S FREE FLY STORIES

03:25
09/25/18
09/25
03:25
09/25/18
03:25
General news
FX Action: USD-CAD has settled in the mid 1.2900s »

FX Action: USD-CAD has…

03:05
09/25/18
09/25
03:05
09/25/18
03:05
General news
FX Update: Most pairings and cross rates have posted narrow ranges »

FX Update: Most pairings…

ASPS

Altisource

$34.41

0.31 (0.91%)

02:55
09/25/18
09/25
02:55
09/25/18
02:55
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

02:10
09/25/18
09/25
02:10
09/25/18
02:10
General news
FX Action: USD-JPY posted a two-month high »

FX Action: USD-JPY posted…

01:35
09/25/18
09/25
01:35
09/25/18
01:35
General news
Asian Market Wrap: »

Asian Market Wrap:…

FDS

FactSet

$231.53

-0.05 (-0.02%)

, JBL

Jabil

$30.08

0.22 (0.74%)

20:25
09/24/18
09/24
20:25
09/24/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FDS

FactSet

$231.53

-0.05 (-0.02%)

JBL

Jabil

$30.08

0.22 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 13

    Nov

LOXO

Loxo Oncology

$163.07

3.91 (2.46%)

20:16
09/24/18
09/24
20:16
09/24/18
20:16
Hot Stocks
Loxo Oncology granted orphan status for solid tumors treatment »

The FDA granted Loxo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

PTLA

Portola Pharmaceuticals

$27.16

-0.39 (-1.42%)

20:15
09/24/18
09/24
20:15
09/24/18
20:15
Hot Stocks
Portola granted orphan status for cerdulatinib »

The FDA granted Portola…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Dec

TNC

Tennant

$72.75

-1.15 (-1.56%)

20:01
09/24/18
09/24
20:01
09/24/18
20:01
Hot Stocks
Tennant to Acquire Gaomei Cleaning Equipment Company, terms not stated »

Tennant Company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$73.52

-1.58 (-2.10%)

19:20
09/24/18
09/24
19:20
09/24/18
19:20
Hot Stocks
Vornado now owns 100% interest in retail condo at Marriott Marquis Times Square »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

, GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

19:08
09/24/18
09/24
19:08
09/24/18
19:08
Periodicals
Google CEO to meet with top Republican lawmakers Friday, WSJ says »

Google CEO Sundar Pichai…

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 03

    Mar

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

, BAS

Basic Energy

$9.44

0.18 (1.94%)

18:56
09/24/18
09/24
18:56
09/24/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ascena…

ASNA

Ascena Retail

$4.02

-0.21 (-4.96%)

BAS

Basic Energy

$9.44

0.18 (1.94%)

KEG

Key Energy

$13.46

-0.18 (-1.32%)

PSTI

Pluristem

$1.31

(0.00%)

ARNA

Arena Pharmaceuticals

$42.80

-1.05 (-2.39%)

NOVN

Novan

$2.72

0.015 (0.56%)

SNDX

Syndax

$7.23

0.46 (6.79%)

DCPH

Deciphera

$39.80

0.78 (2.00%)

BJ

BJ's Wholesale

$28.47

-0.68 (-2.33%)

PETQ

PetIQ

$41.07

-0.55 (-1.32%)

CNP

CenterPoint Energy

$27.81

-0.23 (-0.82%)

CTL

CenturyLink

$22.90

-0.04 (-0.17%)

PBR

Petrobras

$11.40

-0.105 (-0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 28

    Oct

  • 08

    Nov

  • 27

    Nov

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

PBR

Petrobras

$11.40

-0.105 (-0.91%)

18:54
09/24/18
09/24
18:54
09/24/18
18:54
Hot Stocks
Breaking Hot Stocks news story on Petrobras »

Petrobras reports August…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSN

VeriSign

$158.97

-0.79 (-0.49%)

18:39
09/24/18
09/24
18:39
09/24/18
18:39
Recommendations
VeriSign analyst commentary at JPMorgan »

VeriSign price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TI

Telecom Italia

$6.54

-0.1 (-1.51%)

18:35
09/24/18
09/24
18:35
09/24/18
18:35
Periodicals
Telecom Italia discussed Nextel bid at board meeting, Bloomberg says »

Telecom Italia's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSG

Inseego

$4.01

-0.08 (-1.96%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Hot Stocks
Inseego names John Weldon to head Enterprise SaaS Solutions division »

Inseego announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$46.30

-0.48 (-1.03%)

18:31
09/24/18
09/24
18:31
09/24/18
18:31
Periodicals
PG&E says will invest $360M in electric car infrastructure, Bloomberg says »

PG&E senior manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 08

    Oct

  • 11

    Nov

KKR

KKR

$28.25

-0.01 (-0.04%)

18:21
09/24/18
09/24
18:21
09/24/18
18:21
Hot Stocks
KKR announces intra-quarter Q3 monetization activity »

KKR announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$267.35

0.6 (0.22%)

, EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

18:17
09/24/18
09/24
18:17
09/24/18
18:17
Periodicals
UnitedHealth tells Hospitals about Envision ER contracts, Reuters says »

UnitedHealth (UNH) plans…

UNH

UnitedHealth

$267.35

0.6 (0.22%)

EVHC

Envision Healthcare

$45.72

0.07 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 16

    Oct

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

, UBER

Uber

$0.00

(0.00%)

18:14
09/24/18
09/24
18:14
09/24/18
18:14
Periodicals
Amazon has made two approaches to buy Deliveroo, Telegraph reports »

Amazon has made two…

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

UBER

Uber

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BK

BNY Mellon

$52.36

-0.9 (-1.69%)

17:48
09/24/18
09/24
17:48
09/24/18
17:48
Hot Stocks
BNY Mellon Investment Management to close EACM Advisors »

BNY Mellon Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

EPZM

Epizyme

$10.23

-0.075 (-0.73%)

17:44
09/24/18
09/24
17:44
09/24/18
17:44
Initiation
Epizyme initiated at Leerink »

Epizyme initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 02

    Oct

NAVB

Navidea

$0.25

-0.0135 (-5.14%)

17:31
09/24/18
09/24
17:31
09/24/18
17:31
Hot Stocks
Breaking Hot Stocks news story on Navidea »

John K. Scott, Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYL

Dragon Victory

$1.46

(0.00%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Dragon Victory »

White Knight Ltd reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

, RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

17:30
09/24/18
09/24
17:30
09/24/18
17:30
Periodicals
Shell CEO weighs $30B LNG export terminal in Canada, WSJ says »

Royal Dutch Shell CEO Ben…

RDS.A

Royal Dutch Shell

$68.18

0.89 (1.32%)

RDS.B

Royal Dutch Shell

$70.25

0.67 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.